You are here: Home » PTI Stories » National » News
Business Standard

Eli Lilly enters autoimmune segment in India with launch of Olumiant

Press Trust of India  |  New Delhi 

Drug firm Thursday said it has entered the autoimmune segment in with launch of Olumiant, a new once-daily for treatment of rheumatoid

Olumiant is approved in more than 50 countries across the world, it said.

"Lilly is excited to announce the introduction of its for patients living with rheumatoid arthritis," (India) MD said.

Olumiant is an effective, advanced once-daily oral treatment option for people suffering from rheumatoid who have not responded well to conventional disease-modifying anti-rheumatic drugs (DMARDs), he added.

The product will be available in in 4mg and 2mg dosage forms, the company said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, October 11 2018. 16:35 IST